Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Stock Has Average Price Target of $39.67 According to Analysts

Pharming Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five brokerages that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $39.67.

A number of research firms have issued reports on PHAR. Wall Street Zen upgraded shares of Pharming Group from a "hold" rating to a "strong-buy" rating in a research report on Sunday, November 1st. Zacks Research upgraded Pharming Group from a "strong sell" rating to a "hold" rating in a research note on Friday, October 23rd. Oppenheimer reaffirmed an "outperform" rating on shares of Pharming Group in a research report on Wednesday, October 28th. HC Wainwright reiterated a "buy" rating and set a $37.00 price target on shares of Pharming Group in a report on Tuesday, September 22nd. Finally, Canaccord Genuity Group increased their price objective on shares of Pharming Group from $38.00 to $41.00 and gave the company a "buy" rating in a research report on Thursday, October 29th.

Check Out Our Latest Report on PHAR

Pharming Group Stock Performance

NASDAQ:PHAR opened at $11.54 on Friday. The stock has a market capitalization of $816.80 million, a P/E ratio of 36.06 and a beta of -0.05. Pharming Group has a 1 year low of $9.11 and a 1 year high of $21.34. The firm has a 50 day moving average of $11.06 and a 200-day moving average of $13.31. The company has a current ratio of 3.23, a quick ratio of 2.65 and a debt-to-equity ratio of 0.32.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its earnings results on Tuesday, October 27th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.21 by $0.09. The company had revenue of $117.60 million for the quarter, compared to analysts' expectations of $117.60 million. Pharming Group had a return on equity of 8.70% and a net margin of 6.23%. As a group, sell-side analysts anticipate that Pharming Group will post 0.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP purchased a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,148,144 shares of the company's stock, valued at approximately $29,838,000. Pharming Group makes up 6.0% of MAC Alpha Capital Management LP's portfolio, making the stock its 2nd largest position. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group as of its most recent filing with the Securities and Exchange Commission. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

(Get Free Report)

Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

Recommended Stories

Analyst Recommendations for Pharming Group (NASDAQ:PHAR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pharming Group Right Now?

Before you consider Pharming Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.

While Pharming Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines